• Happy Holidays from Cafepharma! To allow its staff to spend holiday time with their families, the Cafepharma Message Boards will be switched to read-only from 6:00 PM Eastern time on Tuesday, December 24 until 10:00 PM Eastern time on Wednesday, December 25. During this time, all posts will be available for view. However, no one will be able to make new posts during this time.


Regenerative Medicine







Anonymous said:
Nope no decision probably going to be pushed back another year at least.
Click to expand...

It's sort of funny how some people believe everything that a pharmaceutical sales manager says on a conference call. Just because your manager says it might not happen doesn't mean it is true. You go ahead and trust your future in what sarah sales manager says. Our days of selling 8 Dermagrafts per patient are done. The government is on to us. Over $10,000 per ulcer? That is robbery and CMS now knows about our scam.
 






Anonymous said:
Its obvious that the above posters are trolls- most likely working for mimedix, running out of your guarantee, and realizing that you cant make commission on samples or credits for reimbursement that didn't go through as promised.
Anyone that is here could easily check on the sales reports and see the current AM's...
Go fish somewhere else-
And also... in the end it will be the inferior wannabe products like yours that will be hurt by the revised CMS ruling...
Click to expand...

Right Genius. CMS is going to put an end to competition. Yeah, that's why CMS has imposed bidding programs, right?

CMS wants commoditization and what best then to pit all the companies against each other for a price. Shire will be squeezed out before others can do it cheaper.
 






Anonymous said:
Show us your information on this. Where is this written? All we have is the information from CMS stating that this will take place in 2014. I can't believe what a group of idiots we have working here.
Click to expand...

Go read cms. It was a proposal for a rule for 2014. Open letter period ended in sept. With decision to be made in Nov. nothing is final. With American Medical Assoc. being completely against the proposal it doesnt help its chance. But like i said nothing is final.
 












It's called a PROPOSED rule. Do you have any idea how many of these proposed rules come out from the CMS that get changed significantly or never get changed at all?

And covering PMA approved products that may cost more (not just DG)- that might actually heal a wound -is nothing compared to what it costs to treat a wound that gets treated with nothing more then a glorified dressing and doesn't heal, gets infected...
You know the rest of the story.
 






That's the whole point...this makes sense to US but insurance companies, CMS, etc. they do not think like that and therefore do not make decisions that actually make sense.

We are not going to survive this. What our inexperienced, pharma managers have relayed to us isn't accurate. I don't know if they're also being fed a line of crap or if they're trying to sugar coat it. (or what would be par for the course is that whoever is supposed to be "in charge" of RM honestly does not know what's going on/understand the severe implications of this and therefore entire division is in the dark) Without CMS we can't survive on private and cash paying. And that whole "write a letter for coverage" when Noridian screwed us over, that worked out really well! NOT.
 






Anonymous said:
That's the whole point...this makes sense to US but insurance companies, CMS, etc. they do not think like that and therefore do not make decisions that actually make sense.

We are not going to survive this. What our inexperienced, pharma managers have relayed to us isn't accurate. I don't know if they're also being fed a line of crap or if they're trying to sugar coat it. (or what would be par for the course is that whoever is supposed to be "in charge" of RM honestly does not know what's going on/understand the severe implications of this and therefore entire division is in the dark) Without CMS we can't survive on private and cash paying. And that whole "write a letter for coverage" when Noridian screwed us over, that worked out really well! NOT.
Click to expand...

Noridian was changed within a few months because of advoacte support of letters and calls...don't know what you are smoking but you have no clue asshole!
 






This is from an unbiased, investment perspective on wound care - from Seeking Alpha -

Conclusion

We see big changes coming to the wound care market starting in 2014. The big players, Dermagraft and Apligraf, two products that each generate over $100 million in annual sales, are on their way out. Newcomers like Grafix will be dead in the water before even getting out of gate. Osiris has a market capitalization of $575 million and seems to have gone all-in on Grafix with the announcement earlier in the month to out-license Prochymal.

The three potential winners we've listed above, ULURU, Cytomedix, and Avita Medical are tiny. ULURU is virtually unknown in the U.S. Similar to Avita, the company's roots trace back to Europe and Australia. But we think Altrazeal®, for lack of a better phrase, is a pretty-damn cool product, and about one or two major data points away from going from obscurity to tens of millions in sales. AutoloGel™ is a product that has been disadvantaged, under-reimbursed, and mischaracterized for over a decade. However, the company has made enormous progress recently with CMS, and reimbursement starting in 2014 should allow AutoloGel™ sales to take off in a hockey-stick like ramp. As for Avita, the product is simply the best option we've see for serious pediatric burns and scalds. After all, how can you not love a product that can do this (source: Dr. Jeremy M. Rawlins FRCS):
 












Anonymous said:
This is from an unbiased, investment perspective on wound care - from Seeking Alpha -

Conclusion

We see big changes coming to the wound care market starting in 2014. The big players, Dermagraft and Apligraf, two products that each generate over $100 million in annual sales, are on their way out. Newcomers like Grafix will be dead in the water before even getting out of gate. Osiris has a market capitalization of $575 million and seems to have gone all-in on Grafix with the announcement earlier in the month to out-license Prochymal.

The three potential winners we've listed above, ULURU, Cytomedix, and Avita Medical are tiny. ULURU is virtually unknown in the U.S. Similar to Avita, the company's roots trace back to Europe and Australia. But we think Altrazeal®, for lack of a better phrase, is a pretty-damn cool product, and about one or two major data points away from going from obscurity to tens of millions in sales. AutoloGel™ is a product that has been disadvantaged, under-reimbursed, and mischaracterized for over a decade. However, the company has made enormous progress recently with CMS, and reimbursement starting in 2014 should allow AutoloGel™ sales to take off in a hockey-stick like ramp. As for Avita, the product is simply the best option we've see for serious pediatric burns and scalds. After all, how can you not love a product that can do this (source: Dr. Jeremy M. Rawlins FRCS):
Click to expand...


This analyst doesn't work in medical. The three products below are trash. Epifix will be the winner because they can cover 75% of DFUs @ 300 bucks ea and do it more effectively than Dermagraft / Apligraf.

The *SMART* thing to do is to buy Mimedx (MDXG) stock to make up for the loss in pay.
 






Anonymous said:
This analyst doesn't work in medical. The three products below are trash. Epifix will be the winner because they can cover 75% of DFUs @ 300 bucks ea and do it more effectively than Dermagraft / Apligraf.

The *SMART* thing to do is to buy Mimedx (MDXG) stock to make up for the loss in pay.
Click to expand...

Read the whole article. It is easy to find. Epifix might do okay, but the article outlines why DG and Apligraf will be done. Epifix will have trouble as well. Wound Centers will be changing the way they do business. No longer will they be pushing grafts. DG will go from $24 million per quarter to $3 million overnight. No more reps.
 






Anonymous said:
Read the whole article. It is easy to find. Epifix might do okay, but the article outlines why DG and Apligraf will be done. Epifix will have trouble as well. Wound Centers will be changing the way they do business. No longer will they be pushing grafts. DG will go from $24 million per quarter to $3 million overnight. No more reps.
Click to expand...

I read the article. What do you think the physicians will use when it's no longer financially feasible to use Dermagraft and Apligraf? Switch to Pixiedust and band aids?

DFUs will still be coming into the clinics regardless of the CMS proposal. Again, the 3 products are trash that's why those stocks aren't moving. The price action of stocks can tell you what the trends are.

The companies that can produce things that are cheaper / cost effective will continue to succeed in the marketplace. Remember, the proposal doesn't end the use of grafts, it only limits what can be paid.
 












Anonymous said:
Noridian was changed within a few months because of advoacte support of letters and calls...don't know what you are smoking but you have no clue asshole!
Click to expand...


Wow! This doesn't scream pharma at all...ha! "because of advocate support of letters and calls" YOU are the one smoking something. Did you get that script memorized for proper roll out of that "letter writing campaign" from your RD too? What a joke. Instead of "how many IVR's did you get today?" did your manager ask you how many letters you got written!! classic! And just so you're accurately informed, not every state changed this "a few months later." Thanks Shire for properly adjusting our quotas, too, much appreciated.
 






Anonymous said:
This analyst doesn't work in medical. The three products below are trash. Epifix will be the winner because they can cover 75% of DFUs @ 300 bucks ea and do it more effectively than Dermagraft / Apligraf.

The *SMART* thing to do is to buy Mimedx (MDXG) stock to make up for the loss in pay.
Click to expand...

Seeking Alpha is FAR from an unbiased source. It is like reading The National Enquirer for your news source. They are all about trying to stir the pot.

This proposed rule will no go through as is, and when it does - bye bye wanna be's like Mimedix.
 






Anonymous said:
Seeking Alpha is FAR from an unbiased source. It is like reading The National Enquirer for your news source. They are all about trying to stir the pot.

This proposed rule will no go through as is, and when it does - bye bye wanna be's like Mimedix.
Click to expand...
Make no mistake about it, when it goes through, Dermagraft will be the first to be finished.
 






Anonymous said:
Make no mistake about it, when it goes through, Dermagraft will be the first to be finished.
Click to expand...

This is such a "my dad can kick your dad's butt" discussion.

Let's say you are spot on and Dermagraft goes belly up. The question I would be asking if I were a Mimedix rep is how many of those little discs would I need to sell to make $200K a year. Yes, you might have a cheaper alternative that wound care centers could apply and still eek out a profit, but your money makers will NEVER go on.

Good luck with that...
 






Anonymous said:
Seeking Alpha is FAR from an unbiased source. It is like reading The National Enquirer for your news source. They are all about trying to stir the pot.

This proposed rule will no go through as is, and when it does - bye bye wanna be's like Mimedix.
Click to expand...

300 bucks for 75% of DFUs. CMS will be joyful. Pixiedust or the status quo. Make your arguement.
 






Anonymous said:
What's up with all of these conference calls where they are mandating us going room to room with the docs? Call it what you want - but these are preceptorships and they are illegal. Wait till the OIG gets a hold of this. We are forced to observe private patient interaction that has nothing to do with an application, thawing, etc. One of my program directors asked their hospital lawyer about this. He said if we are being pushed to do this we should report it. I did.
Click to expand...

This is a real problem for dg if this hipaa non compliance leaks out. Beware
 






You must log in or register to reply here.
Top Bottom
Back